Join +750K new investors every month who copy stock picks from billionaire's portfoliosSign Up Free

Novavax Up 20% As Data Shows Vaccine’ Effective Against Coronavirus, New Strains

Published 12/03/2021, 12:51
Updated 12/03/2021, 12:54
©  Reuters
NVAX
-

By Dhirendra Tripathi

Investing.com – Novavax (NASDAQ:NVAX) shares were up by a fifth in premarket trading Friday after data from a late-stage trial showed that its vaccine is effective against the original Covid-19 strain as well as its variants. The shares exchanged hands at $225.

The company has done trials in the U.K. and South Africa.

The company’s vaccine candidate has been found to be effective against “mild, moderate and severe disease caused by the original COVID-19 strain”, according to a company release.

Final analysis of the trial in the U.K. showed that the vaccine is 96.4% effective against the original coronavirus. It is 86.3% effective against the variant first observed in the U.K., which is fast becoming the dominant strain of the disease in much of Europe. Overall vaccine efficiency is 89.7%.

Efficacy against the strain first observed in South Africa was lower, at 60%. The company has so far only conducted stage 2 trials in South Africa.

Novavax expects the data to serve as the basis for submission for authorization to various regulatory agencies worldwide.

 

 

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.